These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25006198)

  • 1. Proteins in blood reveal pancreatic tumors.
    Schmidt C
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25006198
    [No Abstract]   [Full Text] [Related]  

  • 2. CA 19-9 and pancreatic carcinoma, a revival?
    Ducreux M; Boige V; Malka D
    Onkologie; 2007 Feb; 30(1-2):12-3. PubMed ID: 17264520
    [No Abstract]   [Full Text] [Related]  

  • 3. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
    Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
    Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
    Hámori J; Arkosy P; Lenkey A; Sápy P
    Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis.
    Gentiloni N; Caradonna P; Costamagna G; D'Ostilio N; Perri V; Mutignani M; Febbraro S; Tinari N; Iacobelli S; Natoli C
    Am J Gastroenterol; 1995 Jul; 90(7):1069-72. PubMed ID: 7611198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary.
    Pezzilli R; Casadei R; Calculli L; Santini D; Morselli-Labate AM;
    Dig Liver Dis; 2010 Jan; 42(1):73-4. PubMed ID: 19473891
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions.
    Cwik G; Wallner G; Skoczylas T; Ciechanski A; Zinkiewicz K
    Arch Surg; 2006 Oct; 141(10):968-73; discussion 974. PubMed ID: 17043274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The diagnostic value of determining the level of the carbohydrate antigen 19-9 in pancreatic cancer].
    Moroz GS; Les'kiv IM
    Klin Khir (1962); 1993; (2):34-5. PubMed ID: 10912065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
    Markocka-Maczka K
    Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
    Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA 19-9: not a magic marker for pancreatic cancer.
    Daram SR
    South Med J; 2006 Mar; 99(3):205. PubMed ID: 16553091
    [No Abstract]   [Full Text] [Related]  

  • 16. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
    Santander C; Jiménez I; Martín E; Melón A; Pajares JM
    Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer.
    Go VL
    Pancreas; 1994 Nov; 9(6):673. PubMed ID: 7846009
    [No Abstract]   [Full Text] [Related]  

  • 19. Is CA 19-9 useful in the management of pancreatic cancer?
    Balzano G; Di Carlo V
    Lancet Oncol; 2008 Feb; 9(2):89-91. PubMed ID: 18237847
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
    Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
    Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.